Core Viewpoint - Guangkang Biochemical experienced a significant stock price surge followed by a sharp decline, indicating a disconnect between its stock performance and fundamental financial health [1][3]. Group 1: Stock Performance - On June 4, Guangkang Biochemical opened with a drop exceeding 13%, following a remarkable increase of 68% over five trading days from May 25 to June 3, where the stock price rose from 26.53 yuan to a peak of 48 yuan [1][3]. - The stock's volatility was exacerbated by speculative trading, with institutional investors and retail traders actively participating in the market [5][6]. Group 2: Financial Performance - The company's net profit decreased from 96.17 million yuan in 2022 to 34.68 million yuan in 2024, representing a decline of approximately 64% [4]. - In the first quarter of 2025, the net profit continued to decline, showing a year-on-year decrease of 3.17% [4]. Group 3: Shareholder Actions - Following the stock price surge, major shareholders announced plans to reduce their holdings, with a total potential reduction of up to 6% of shares, equating to approximately 198 million yuan in cash [8][9]. - The significant selling pressure from shareholders, including private equity funds, indicates a lack of confidence in the stock's future performance [8][9]. Group 4: Market Dynamics - The initial stock price increase was driven by speculation around innovative drug concepts and anticipated supply shortages of chlorantraniliprole, a key product for Guangkang Biochemical [4][3]. - The innovative drug sector saw a notable rise, with the relevant index increasing from 1163 points to 1293 points during the same period [3].
300804，急涨后暴跌，啥情况？